WorldUpstart Announces Companies Selected for the Winter 2025 U.S. Market Gateway Accelerator
WorldUpstart U.S. Market Gateway Accelerator Companies - Winter 2025
For Immediate Release: Philadelphia, PA (11. February, 2025) – WorldUpstart proudly announces the launch of its Winter 2025 U.S. Market Gateway Accelerator, featuring ten innovative Life Science and MedTech companies poised for significant growth. This 8-week hybrid program, commencing online on February 10, 2025, culminates in a high-impact visit to Philadelphia from May 5-6, 2025.
This year's participants were selected from a competitive pool of over 100 applicants, including startups and established companies specializing in Drug Development, Medical Devices, and Digital Health from around the globe. The chosen companies, representing Canada, France, India, Israel, Italy, Norway, Poland, Sweden, Switzerland, and the United Kingdom, are set to embark on a journey to expand into the dynamic U.S. market. Through WorldUpstart's intensive accelerator program, these companies will gain valuable insights, mentorship, and access to strategic networks, providing them with the tools and support needed for a successful market entry.
"The U.S. market is evolving, offering new challenges but also more opportunities than ever for innovation and global collaboration. Yet, for foreign companies, navigating this dynamic landscape can still be complex," said Karina Sotnik, Founder and CEO of WorldUpstart. "Our soft-landing program, enriched by insights from top experts and trusted industry veterans, provides a tailored strategic roadmap to help companies not only enter the U.S. market but also scale successfully in this era of transformation."
Meet the Winter 2025 Cohort
SmartCella is advancing the next generation of targeted therapeutics through their FDA-approved endovascular delivery system Extroducer, and in-house R&D to produce effective mRNA, cell-based and stem-cell derived therapeutics.
WPD Pharmaceuticals is dedicated to developing novel highly-selective targeted cancer therapeutics with a focus on Glioblastoma, Triple Negative Breast Cancer and larger-scale multi-cancer therapies.
Medical Templates specializes in building tools to aid in the delivery of precision medicine and interventional radiology, through their Cube Navigation System platform, a proprietary platform built to improve needle alignments and plan efficient procedures.
MathBiology’s novel platform called Deep Metabolism Assessment makes early detection of illnesses possible by monitoring electrical impulses and the metabolism of a person’s organs, adding the ability to account for personal health.
HoloCare provides a platform to convert standard CT and MRI scans into intuitive, spatial holograms. Clinicians can manipulate these holograms—moving, rotating, and expanding them—to view organs from any angle, facilitating precise pre-operative planning.
Vera Healthcare is building a digital smartphone platform (VeraScan) to utilize retinal scanning technology for preventative and diagnostic screening for diabetic retinopathy to better detect and manage varying types of diabetes from pre-diabetes, type 1, 2, and gestational.
BOTdesign has developed an innovative suite of digital health applications (MAX, HEKO, ORIGA) designed to improve the efficiency and quality of medical care and increase provider-patient interaction time.
Medwise.ai offers an AI-powered search platform that enables clinicians to quickly find concise and actionable answers to clinical questions at the point of care.
IPtoki is improving the security of digital medical infrastructure by developing a unique individualized password signature (IAMMYID) based on behavioral biometrics such as gait, gestures, motion and keystrokes.
Mediary empowers your providers with live coding guidance, ensuring every claim is accurate, compliant, and optimized for revenue.
About WorldUpstart
WorldUpstart empowers international Life Sciences, MedTech, and Digital Health companies to successfully enter and expand in the U.S. market. The U.S. Market Gateway Accelerator equips participants with the tools to navigate entry challenges, craft strategic expansion roadmaps, and forge vital connections with industry leaders, partners, and investors. In just four years, the program has supported 83 companies from 20 countries, with 40% establishing a U.S. presence and nine securing FDA approvals.
Given that only 1 in 5 of international companies typically succeed in breaking into the U.S. market, WorldUpstart’s Accelerator has doubled that success rate—transforming how global innovators approach U.S. expansion.
